Combined Therapy With the RANKL Inhibitor RANK-Fc and rhApo2L/TRAIL/dulanermin Reduces Bone Lesions and Skeletal Tumor Burden in a Model of Breast Cancer Skeletal Metastasis
Cancer Biology and Therapy - United States
doi 10.4161/cbt.9.7.11266
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2010
Authors
Publisher
Informa UK Limited